-
Mashup Score: 0
Previous studies and clinical observations have suggested that antibiotics during immunotherapy treatment may hasten negative outcomes.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2What's Next for Immunotherapy in Biliary Tract Cancers? - 1 year(s) ago
The combination of gemcitabine and cisplatin (GC) has been considered the standard of care for the first-line treatment of patients with advanced biliary tract cancer (BTC) for more than a decade.
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Beyond TOPAZ-1: What’s next for IO in the treatment of #BiliaryTract cancers? Two GI medical oncologists at @MDAndersonNews investigate for #ASCODailyNews: https://t.co/NEqaXJlVX4 #GI23 #gicsm
-
-
Mashup Score: 0The Cancer News Daily - 2 year(s) ago
The latest in cancer medicine and translational research by Wafik El-Deiry MDPhD
Source: paper.liCategories: Latest Headlines, Oncologists2Tweet-
The latest The Cancer News Daily! https://t.co/7YID59KVx1 Thanks to @CathyEngMD @HemOncToday @theNCI #icymi #biliarytract
-
-
Mashup Score: 3
Gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety in patients with biliary tract cancer. Gemcitabine and cisplatin plus durvalumab are being evaluated in the phase 3, TOPAZ-1 study (NCT03875235) as first-line treatment in patients with advanced biliary tract cancer.
Categories: Gastroenterology, Latest HeadlinesTweet-
New research - Oh et al - Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced #biliarytract #cancer: an open-label, single-centre, phase 2 study https://t.co/frkOqAhr9S #GITwitter #OncTwitter https://t.co/peobBPvRc0
-
-
Mashup Score: 6
Dabrafenib plus trametinib combination treatment showed promising activity in patients with BRAFV600E-mutated biliary tract cancer, with a manageable safety profile. Routine testing for BRAFV600E mutations should be considered in patients with biliary tract cancer.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In our Sept issue: #Dabrafenib plus #trametinib in patients with BRAFV600E-mutated #biliarytract #cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial https://t.co/rxaLuft007
-
-
Mashup Score: 1
Peruse the current issue of The Lancet Oncology, a monthly journal covering international issues relevant to clinical cancer specialists worldwide
Source: www.thelancet.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our Sept is now live! Read our 20th anniversary issue here: https://t.co/LE3Rmwo3bb For papers on #headandneck #cancer, #biliarytract cancer, #breast cancer, #CLL, #mesothelioma, #neuroendocrine tumours & more https://t.co/QRkDbcEuew
-
-
Mashup Score: 1
Peruse the current issue of The Lancet Oncology, a monthly journal covering international issues relevant to clinical cancer specialists worldwide
Source: www.thelancet.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our Sept issue is now live! Read it here: https://t.co/LE3RmwFE2J For papers on #headandneck #cancer, #biliarytract cancer, #breast cancer, #CLL, #mesothelioma, #neuroendocrine tumours & more https://t.co/2ZBtfsh23J
-
-
Mashup Score: 3
Dabrafenib plus trametinib combination treatment showed promising activity in patients with BRAFV600E-mutated biliary tract cancer, with a manageable safety profile. Routine testing for BRAFV600E mutations should be considered in patients with biliary tract cancer.
Source: The Lancet OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Online first: #Dabrafenib plus #trametinib in patients with BRAFV600E-mutated #biliarytract #cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial https://t.co/rxaLuft007
-
#Immunotherapy with #Antibiotics doesn’t worsen #BiliaryTract #Cancer outcomes 👉https://t.co/wCwldlGBTs @MDedgeHemOnc @Rdotinga #BiliaryCancer https://t.co/YC6dg1AHF1